

Renal cell carcinoma

James J. Hsieh¹, Mark P. Purdue², Sabina Signoretti³, Charles Swanton⁴, Laurence Albiges⁵, Manuela Schmidinger⁶, Daniel Y. Heng⁷, James Larkin⁸ and Vincenzo Ficarra⁹

Abstract | Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. Although somatic *VHL* mutations have been described for some time, more-recent cancer genomic studies have identified mutations in epigenetic regulatory genes and demonstrated marked intra-tumour heterogeneity, which could have prognostic, predictive and therapeutic relevance. Localized RCC can be successfully managed with surgery, whereas metastatic RCC is refractory to conventional chemotherapy. However, over the past decade, marked advances in the treatment of metastatic RCC have been made, with targeted agents including sorafenib, sunitinib, bevacizumab, pazopanib and axitinib, which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and everolimus and temsirolimus, which inhibit mechanistic target of rapamycin complex 1 (mTORC1), being approved. Since 2015, agents with additional targets aside from VEGFR have been approved, such as cabozantinib and lenvatinib; immunotherapies, such as nivolumab, have also been added to the armamentarium for metastatic RCC. Here, we provide an overview of the biology of RCC, with a focus on ccRCC, as well as updates to complement the current clinical guidelines and an outline of potential future directions for RCC research and therapy.

Renal cell carcinoma (RCC) encompasses a heterogeneous group of cancers derived from renal tubular epithelial cells¹ and is among the 10 most common cancers worldwide. Key advances in histopathological and molecular characterization of RCC over the past two decades have led to major revisions in its classification^{2–5}. Major subtypes⁶ with $\geq 5\%$ incidence are clear cell RCC (ccRCC)⁷, papillary RCC (pRCC)⁸ and chromophobe RCC (chRCC)⁹ (FIG. 1). The remaining subtypes are very rare (each with $\leq 1\%$ total incidence)⁵, and in cases in which a tumour does not fit any subtype in the diagnostic criteria, it is designated as unclassified RCC (uRCC; $\sim 4\%$ total incidence)¹⁰. ccRCC is the most common subtype and accounts for the majority of deaths from kidney cancer and is the focus of this Primer¹¹. Indeed, owing to the predominance of clear cell histology in metastatic disease (83–88%)^{12,13}, tumours with non-clear-cell histology have been grouped as ‘nccRCC’ (TABLE 1) for feasibility in conducting clinical trials^{14–16}. Furthermore, recent cancer genomic studies have revealed an overt complexity of intra-tumour^{17–19} and inter-tumour^{7,20} heterogeneity in ccRCC, which could contribute to the heterogeneous clinical outcomes observed^{21–23}.

Localized RCC can be treated with partial or radical nephrectomy (removal of the kidney)²⁴, ablation (destruction of the malignant tissue with heat or cold)²⁵ or active surveillance (monitoring of tumour growth with periodic radiographic studies)²⁶. Despite nephrectomy with curative intent, $\sim 30\%$ of patients with ccRCC with localized disease eventually develop metastases^{27–30}, which require systemic therapies and are associated with high mortality. Targeted therapies against vascular endothelial growth factor (VEGF) and mechanistic target of rapamycin (mTOR) pathways have been developed, but treatment response is varied and most patients eventually progress³¹. However, increased genomic and molecular understanding of metastatic ccRCC has contributed to an unprecedented number of drug approvals in the United States and European Union (currently, 12 approved drugs with six different effective mechanisms of action are approved). In this Primer, we discuss these new approvals and the major progress that has made in the biology of ccRCC that led to their development. Furthermore, we present insights into genomic-based risk and treatment stratification and discuss treatment sequencing and combinations that are paving the way for the future design of personalized clinical management plans.

Correspondence to J.J.H. Molecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8069, St. Louis, Missouri 63110, USA.
jhsieh@wustl.edu

Article number: 17009
doi:10.1038/nrdp.2017.9
Published online 9 Mar 2017

Author addresses

¹Molecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8069, St. Louis, Missouri 63110, USA.

²Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.

³Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

⁴Francis Crick Institute, UCL Cancer Institute, CRUK Lung Cancer Centre of Excellence, London, UK.

⁵Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.

⁶Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

⁷Department of Medical Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.

⁸Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK.

⁹Department of Experimental and Clinical Medical Sciences — Urologic Clinic, University of Udine, Udine, Italy.

Epidemiology

Incidence and mortality

Kidney cancer accounts for ~2% of all cancer diagnoses and cancer deaths worldwide, with incidence rates generally higher in developed countries³² (FIG. 2). Annually, ~295,000 new kidney cancer cases are diagnosed and ~134,000 deaths are recorded worldwide^{33,34}. Kidney cancer accounts for ~63,000 new cases and ~14,000 deaths yearly in the United States³⁵, and for ~84,000 new

cases and ~35,000 deaths in Europe³⁶. Men are more affected than women (a 2:1 ratio of new diagnoses).

The median age of patients with RCC in the Surveillance, Epidemiology, and End Results (SEER) database in the United States was 64 years with a near-normal distribution³⁷. Accordingly, when RCC is diagnosed at younger ages (≤ 46 years, which represents the lowest decile of the age distribution)^{37,38}, the possibility of an underlying hereditary kidney cancer syndrome — which accounts for 3–5% of all RCCs⁵ — should be considered^{39,40} (TABLE 2).

The incidence of RCC is highest in the Czech Republic, with age-standardized annual rates of 22.1 and 9.9 new cases per 100,000 men and women, respectively, over the period 2003–2007 (REF. 41). The incidence is also very high in the Baltic and eastern European countries, although the reasons for this excess are not known. Overall, incidence rates have been increasing over time in most populations, but mortality rates have levelled off or have been decreasing since the 1990s. This divergent pattern of increasing incidence and decreasing mortality is particularly evident in developed countries. For example, analyses within the SEER database indicate that the increase in RCC incidence is confined to small and localized tumours, probably owing, at least in part, to the increasingly frequent incidental detection — from increased use of abdominal imaging — of small renal masses (tumours ≤ 4 cm in size) that are unlikely to have metastasized⁴². The global increases in the prevalence of obesity, an established RCC risk factor, might also play a part in increasing incidence, as well as in influencing clinical outcome^{41,43}.

Risk factors

RCC incidence increases markedly with age and is higher for men than for women. In the United States, incidence varies by ethnic group, with rates highest among Native Americans, Indigenous Alaskans and African Americans, and are lowest among Asian Americans and people of Pacific Island descent³⁵. The major established risk factors for RCC include excess body weight, hypertension and cigarette smoking⁴⁴, which were factors in approximately half of all diagnosed cases in one US study⁴⁵. Other medical conditions that have been associated with RCC in epidemiological studies include chronic kidney disease, haemodialysis, kidney transplantation, acquired kidney cystic disease, a previous RCC diagnosis and, possibly, diabetes mellitus⁴⁴.

Many lifestyle, dietary, occupational and environmental factors have also been associated with RCC with varying levels of evidence⁴⁶. For example, contradictory reports exist on the association between red meat consumption and RCC risk^{47,48}. Moderate alcohol consumption (≥ 11 g per day) seems to reduce the risk for RCC^{48,49}. In a case-control study on physical activity and the risk of RCC, inverse trends in risk were found, and the authors concluded that 9% of RCC cases could be avoided by increasing physical activity⁵⁰. However, the inverse association might have involved other confounding factors, such as body mass index (BMI) and social class correlates. Other studies have found no such inverse association⁵¹.




Figure 1 | Distinct subtypes of renal cell carcinoma. Approximately 75% of renal cell carcinomas (RCCs) are clear cell RCC (part a). Papillary RCCs make up ~15% of all kidney cancers and are divided into two types based on staining features: type 1 (basophilic; part b) and type 2 (eosinophilic; part c). Chromophobe RCCs make up ~5% of kidney tumours (part d). Other minor subtypes include MiT family translocation RCCs (part e) and collecting duct RCCs (part f). Additional minor subtypes include medullary RCC, clear cell papillary RCC, acquired cystic disease-associated RCC, tubulocystic RCC, mucinous tubular and spindle RCC, succinate dehydrogenase-deficient RCC, hereditary leiomyomatosis, RCC-associated RCC and oncocytoma. Tumours not fitting into any of these categories are designated as unclassified RCC.

Table 1 | Non-clear-cell renal cell carcinomas

Tumour type	Subtype	Cytogenetic alterations	Genes mutated	Gross appearance	Histological features*
Papillary	Type 1	<ul style="list-style-type: none"> Gains of 7, 8q, 12q, 16p, 17 and 20 Loss of 9p 	<i>MET</i>	<ul style="list-style-type: none"> Mixed cystic or solid consistency Often whitish in colour and may show haemorrhage and necrosis 	<ul style="list-style-type: none"> Single layer of cuboid tumour cells Thin, basophilic papillae with scant pale cytoplasm and low nuclear grade Concentric lamellated calcifications (psammoma bodies) Foamy macrophage infiltration
	Type 2	<ul style="list-style-type: none"> Gains of 8q Loss of 1p and 9p 	<ul style="list-style-type: none"> <i>CDKN2A</i> <i>SETD2</i> <i>NRF2</i> 	<ul style="list-style-type: none"> Frequently with a well-demarcated pseudocapsule 	<ul style="list-style-type: none"> Heterogeneous, thick papillae and eosinophilic cytoplasm, high nuclear grade and pseudostratification Concentric lamellated calcifications Foamy macrophage infiltration
Chromophobe	Classic	Loss of chromosomes 1, 2, 6, 10, 13, 17 and 21	<ul style="list-style-type: none"> <i>TP53</i> <i>PTEN</i> 	<ul style="list-style-type: none"> Large, well-circumscribed grey to tan-brown coloured tumour Occasional central scar 	<ul style="list-style-type: none"> Tumour cells with prominent membrane and pale cytoplasm Voluminous cytoplasm (cytoplasmic accumulation of acid mucopolysaccharides)
	Eosinophilic				<ul style="list-style-type: none"> Large tumour cells with fine eosinophilic granules Distinct cell borders Voluminous cytoplasm
MiT family translocation	NA	Recurrent translocations involving Xp11.23 (<i>TFE3</i>) or 6p21 (<i>TFEB</i>)	<ul style="list-style-type: none"> <i>TFE3</i> <i>TFEB</i> 	<ul style="list-style-type: none"> Yellowish tissue Often studded by haemorrhage and necrosis 	<ul style="list-style-type: none"> Papillary or nested architecture Abundant clear or eosinophilic cytoplasm
Collecting duct	NA	<ul style="list-style-type: none"> Losses at 8p, 16p, 1p and 9p Gains at 13q 	Unknown	<ul style="list-style-type: none"> Partially cystic White-grey appearance Often exhibit invasion into the renal sinus 	<ul style="list-style-type: none"> Tubulopapillary pattern Often with cells taking columnar pattern with hobnail appearance Presence of mucinous material Desmoplastic stroma
Medullary	NA	Poorly described, but thought to be normal karyotype	<i>SMARCB1</i>	<ul style="list-style-type: none"> Tan or white appearance Poorly defined capsule Extensive haemorrhage and necrosis 	<ul style="list-style-type: none"> Poorly differentiated, eosinophilic cells Inflammatory infiltrative cells Sheet-like or reticular pattern is common
Oncocytoma	NA	<ul style="list-style-type: none"> Loss of chromosome 1 and Y chromosome <i>CCND1</i> rearrangement 	Mitochondrial genes (<i>COX1</i> , <i>COX2</i> , <i>MTND4</i> and <i>MTCYB</i>)	<ul style="list-style-type: none"> Mahogany colour Circumscribed Occasional central scar Rarely with necrosis 	<ul style="list-style-type: none"> Polygonal cells with abundant eosinophilic cytoplasm Uniform, round nuclei

NA, not applicable. *No consensus is currently available that describes the immune infiltration of non-clear-cell renal cell carcinomas. Adapted from REF. 208.

Genetic factors also contribute to RCC risk, as evidenced by individuals with a family history of renal cancer having an approximate twofold increased risk⁵². Investigations into familial RCC have uncovered mutations in at least 11 genes (*BAP1*, *FLCN*, *FH*, *MET*, *PTEN*, *SDHB*, *SDHC*, *SDHD*, *TSC1*, *TSC2* and *VHL*), some of which have also been implicated in sporadic RCC development³⁹. A notable example is *VHL* (which encodes pVHL), the mutated gene underlying von Hippel–Lindau disease, which is characterized by a high risk of developing ccRCC⁵³; inactivation of pVHL, which leads to the unchecked expression of oncogenic hypoxia-inducible factor 1 (HIF1) and HIF2, is also a hallmark of sporadic ccRCC tumours (see Mechanisms/pathophysiology)^{39,54}. Genome-wide association studies (GWAS) of RCC have identified six susceptibility loci to date, on chromosome regions 2p21, 2q22.3, 8q24.21, 11q13.3, 12p11.23 and 12q24.31 (REFS 55–58). The 2p21 locus maps to *EPAS1*, which encodes the HIF2 α subunit⁵⁵, whereas the biological effects underlying the 11q13.3 locus seem to be attributable to changes in

the regulation of *CCND1* (encoding cyclin D1, which is involved in cell cycle regulation)⁵⁹. The locus 12p11.23 probably maps to changes in *BHLHE41* (encoding basic helix–loop–helix family member e41, which is thought to have a role in the regulation of the circadian rhythm)⁶⁰. The disease genes underlying the other GWAS susceptibility loci have yet to be identified.

Mechanisms/pathophysiology

Genes and pathways

In ccRCC, the *VHL* tumour suppressor gene is the most frequently mutated gene^{7,54}, and its complete loss through genetic (point mutations, insertions and deletions (indels) and 3p25 loss) and/or epigenetic (promoter methylation) mechanisms constitute the earliest, truncal oncogenic driving event^{61,62}. *VHL* is the substrate recognition component of an E3 ligase complex that ubiquitylates HIF1 α and HIF2 α for proteasome-mediated degradation^{53,63,64}. Thus, loss of *VHL* leads to the aberrant accumulation of HIF proteins despite an adequately oxygenated tissue microenvironment, which




Figure 2 | Global kidney cancer incidence. Estimated age-standardized rates of incidence for both sexes (per 100,000 people) in 2012. Rates are generally higher in developed countries, with the highest incidence in the Czech Republic (reasons why are unknown). Reproduced with permission from Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: <http://globocan.iarc.fr>, accessed on 30/01/2017.

in turn results in uncontrolled activation of HIF target genes that regulate angiogenesis, glycolysis and apoptosis (FIG. 3). Accordingly, human ccRCC tumours are rich in lipids and glycogens, and are highly vascular^{65,66} — which underlies why agents that primarily inhibit VEGF and its receptor VEGFR are effective treatments for metastatic ccRCC^{14,15,67}. However, *VHL* loss alone is insufficient to induce ccRCC, as evidenced by the long latency (>30 years) in individuals who harbour *VHL* germline mutations to develop ccRCC⁵³ and by the observation that *Vhl* loss in mice is unable to induce ccRCC⁶⁸. These results suggest that additional genetic and/or epigenetic events are probably needed for ccRCC to develop⁶⁹.

To identify these events, large-scale cancer genomic projects have been undertaken and have revealed several novel prevalent mutations in ccRCC, including *PBRM1* (29–41% of tumour samples), *SETD2* (8–12%), *BAP1* (6–10%), *KDM5C* (4–7%) and *MTOR* (5–6%)^{7,70–73}. Interestingly, *PBRM1*, *SETD2* and *BAP1* encode chromatin-regulating and histone-regulating proteins, are located at 3p21 and function as tumour suppressors^{7,70–72}. As *VHL* resides at 3p25, a single copy loss of the short arm of chromosome 3 (3p) would result in haploinsufficiency of these four tumour suppressor genes, corroborating the fact that 3p loss (that is, loss of heterozygosity) is nearly a universal event in ccRCC⁶¹ and constitutes an early genetic event⁶⁹. By contrast, *MTOR* mutations in ccRCC are generally missense

and functionally activating^{73,74}, which could explain the reason why mTOR pathway inhibitors, including everolimus and temsirolimus, are effective^{75,76}.

How individual mutations and their interactions contribute to the pathogenesis and their values as prognostic or predictive biomarkers in ccRCC are largely unknown. Nevertheless, a few studies have demonstrated interesting clinical correlations that warrant future validation. As inactivation of *VHL* is the founding event of ccRCC, its mutation status has no effect on clinical outcome, whereas mutations involved in disease progression, such as *PBRM1*, *SETD2* and *BAP1* as well as *KDM5C* (which is also involved in chromatin modification), were shown to associate with aggressive clinical features^{77–79}. Small renal masses harbouring *PBRM1* mutations were associated with stage III pathological features (that is, extrarenal growth but not extending beyond Gerota's fascia, see below)⁷¹, whereas *BAP1* mutations were associated with larger tumour sizes, higher Fuhrman nuclear grade (that is, a large nucleus with a prominent nucleolus) and worse cancer-specific survival^{77,78,80}. Interestingly, mutations in *BAP1* and *PBRM1* (REF. 70) or *KDM5C*²⁰ seem to occur mutually exclusively in ccRCC, offering a molecular subclassification of ccRCC. Furthermore, mutations in *KDM5C*, which is located at Xp11.22, were predominantly detected in male patients and correlated with long-term therapeutic benefit from sunitinib²⁰; mutations in *SETD2* were associated with reduced relapse-free survival⁸⁰.

Table 2 | Hereditary syndromes associated with renal cell carcinoma

Syndrome (phenotype OMIM reference)	Gene (position)	Protein	Incidence of developing a kidney tumour (%)	Median age at diagnosis (years)	Other phenotypic features
Clear cell renal cell carcinoma*					
von Hippel–Lindau disease (193300)	VHL (3p25–26)	pVHL	25–45	40	<ul style="list-style-type: none"> • Haemangioblastoma • Pancreatic neuroendocrine tumours • Pheochromocytoma • Renal cysts • Pancreatic cysts • Ovary cystadenoma • Epididymal cystadenoma
BAP1 mutant disease (also known as tumour predisposition disease; 614327)	BAP1 (3p21)	BRCA-associated protein	No data	No data	<ul style="list-style-type: none"> • Breast cancer • Uveal melanoma • Mesothelioma • Other cutaneous melanocytic tumours
SDH-associated kidney cancer (185470, 602413, 602690 and 115310)	SDHB (1p36), SDHC (1q23) and SDHD (11q23)	Succinate dehydrogenase subunits B, C and D	5–15	30	<ul style="list-style-type: none"> • Paranglioma • Carotid body tumours • Pheochromocytoma • Gastrointestinal stromal tumour
Papillary renal cell carcinoma					
Hereditary leiomyomatosis and renal cell cancer (150800) [‡]	FH (1q43)	Fumarate hydratase	2–21	46	<ul style="list-style-type: none"> • Uterine leiomyosarcomas • Breast cancer • Bladder cancer • Cutaneous leiomyomas • Uterine leiomyomas
Hereditary papillary kidney cancer (605074) [§]	MET (7q31)	Hepatocyte growth factor receptor	No data	<60	No additional features
Multiple tumour types					
Birt–Hogg–Dubé syndrome (135150)	FLCN (17p11.2)	Folliculin	34	50	<ul style="list-style-type: none"> • Fibrofolliculomas and trichodiscomas • Pulmonary cysts • Pneumothorax
Tuberous sclerosis complex (191100 and 191092) [¶]	TSC1 (9q34) and TSC2 (16p13)	Hamartin and tuberlin	2–4	30	<ul style="list-style-type: none"> • Subependymal giant cell astrocytomas • Angiomyolipomas • Renal cysts • Facial angiofibroma • Ungual and periungual fibromas • Hypomelanotic macule • Forehead plaque • Cardiac rhabdomyomas • Connective tissue naevus
Cowden syndrome (also known as multiple hamartoma syndrome; 158350) [#]	PTEN (10q23)	Phosphatase and tensin homologue	34	40	<ul style="list-style-type: none"> • Breast cancer • Endometrial cancer • Thyroid cancer • Prostate cancer • Macrocephaly • Intestinal hamartomatous polyps • Benign skin tumours (multiple trichilemmomas, papillomatous papules and acral keratoses) • Dysplastic gangliocytoma of the cerebellum
Hyperparathyroidism jaw tumour syndrome (145001) ^{**}	HRPT2 (1q31)	Parafibromin	No data	No data	<ul style="list-style-type: none"> • Parathyroid carcinomas • Uterine carcinomas • Renal cysts and hamartomas • Hyperparathyroidism • Parathyroid gland tumours • Jaw fibromas

OMIM, Online Mendelian Inheritance in Man database. *Familial clear cell kidney cancer with chromosome 3 translocation is another possible syndrome associated with clear cell renal cell carcinoma, but the genetic lesions and associated data are unknown. †Main renal cancer type is papillary renal cell carcinoma type 2. ‡Main renal cancer type is papillary renal cell carcinoma type 1. §Main renal cancer types are hybrid tumours, oncocytomas, and chromophobe, papillary and clear cell renal cell carcinomas. ¶Main renal cancer types are angiomyolipomas, epithelioid angiomyolipomas, oncocytomas, and papillary and clear cell renal cell carcinomas; renal cysts also are common. #Main renal cancer types are clear cell, papillary and chromophobe renal cell carcinomas. **Main renal cancer types are mixed tumours (epithelial and connective tissue), papillary renal cell carcinomas and nephroblastomas.

Tumour heterogeneity and cancer evolution

As Nowell first described 40 years ago⁸¹, genetic diversity within tumours is thought to provide the substrate upon which selection can act, to enable tumours to adapt to new microenvironmental pressures and metabolic demands during the natural history of the cancer (FIG. 4a). Such genetic diversity has been studied extensively in ccRCC. For example, in a study of four patients with ccRCC who had multiple tumours and were subjected

to multiregion genetic analysis, *VHL* mutation and 3p loss of heterozygosity were found to be ubiquitous events across all regions sampled¹⁷. By contrast, common driver events, such as *SETD2*, *PBRM1*, *MTOR*, *PIK3CA*, *PTEN* and *KDM5C* mutations, were present heterogeneously within the primary tumour and metastatic sites — in some regions but not others. Such genetic characteristics enable the construction of tumour phylogenies, whereby the ‘trunk’ of the evolutionary tree depicts mutations found in the most recent common ancestor (MRCA) that are also present in every tumour cell. ‘Branched’ mutations are found in some subclones but not others; these mutations may be regionally distributed across the tumour, occupying distinct regional niches within the primary tumour or different niches between the primary and metastatic sites of disease.

Furthermore, parallel evolution has been observed, whereby recurrent branch alterations in subclones affect the same gene, the signal transduction pathway or the protein complex (FIG. 4b). In some cases — such as *BAP1*, *PBRM1* and *SETD2* mutations — such recurrent but distinct alterations can be readily explained as the ‘second-hit’ event in the evolution of the tumour. In other cases, parallel evolution suggests considerable selection pressures for disruption of the same signalling pathway or protein complex. In addition, convergence of genetic characteristics has been noted in several studies of ccRCC^{19,23,82}, whereby mutations in genes occur at different time points but result in similar overall genomic and phenotypic profiles; a ‘braided river’ model has been conceived to illustrate this phenomenon⁶⁹ (FIG. 4c). Regardless of the modality, a follow-up study of ccRCC samples from eight patients demonstrated evidence for branched evolution, in which 73–75% of driver alterations were found to be subclonal¹⁸.

Multiregion tumour analyses suggest the intriguing possibility that evolutionary trajectories are remarkably constrained in ccRCC, which — as our knowledge of microenvironmental, therapeutic and host selection pressures grows — could render the evolutionary routes predictable and, therefore, therapeutically tractable. For example, it has been shown that patients who responded well to mTOR inhibition harboured recurrent regionally separated aberrations in components of the mTOR pathway⁷⁵. Furthermore, some subclonal alterations might be involved in the initiation and maintenance of cell-to-cell variation that are necessary for clonal selection. For example, *SETD2* loss of function has been shown to impair nucleosome compaction, minichromosome maintenance complex component 7 (MCM7) function and DNA polymerase- δ loading to chromatin, resulting in impaired DNA replication fork progression. In addition, failure to load lens epithelium-derived growth factor p75 splice variant (LEDGF; also known as PSIP1) and DNA repair protein RAD51 homologue 1 (RAD51) — which are involved in DNA break repair — has also been observed upon *SETD2* loss, resulting in homologous recombination repair deficiency⁸³. These events are, accordingly, plausible genomic biomarkers in ccRCC that are dispersed within distinct regional niches within each tumour^{19,84}.




Figure 3 | *VHL* inactivation in clear cell renal cell carcinoma and its implication in targeted therapy. Loss of *VHL* (which encodes pVHL) is the most frequent genetic feature of clear cell renal cell carcinoma (ccRCC). Its loss relieves the cell of negative regulation of the hypoxia-inducible factors (HIFs), which results in increased HIF target gene expression and ensuing changes in cellular metabolism and signalling that enhance cell survival. For example, increased vascular endothelial growth factor (VEGF) expression increases angiogenesis in concert with increased growth factor signalling in endothelial cells in the tumour microenvironment (including fibroblast growth factor (FGF) and hepatocyte growth factor (HGF)). Collectively, these changes provide the targets for therapeutic agents to impede tumour growth, as indicated. Dashed inhibitory line indicates indirect inhibition shown in limited reports. EIF4EBP1, eukaryotic translation initiation factor 4E-binding protein 1; FGFR, FGF receptor; HRE, HIF response element; MET, hepatocyte growth factor receptor; mTORC, mechanistic target of rapamycin complex; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homologue; RHEB, GTP-binding protein Rheb; S6K1, ribosomal protein S6 kinase; TSC, tuberous sclerosis complex; VEGFR, VEGF receptor.




Figure 4 | Cancer evolution and tumour heterogeneity in clear cell renal cell carcinoma. Although *VHL* mutation and 3p loss of heterozygosity are early events that are evident in all clear cell renal cell carcinoma (ccRCC) cells regardless of the region of the tumour sampled, common driver mutations (for example, *SETD2*, *MTOR* and *KDM5C* mutations) are present heterogeneously — suggestive of subclonal evolution of the tumour. **a** | Cancer subclones originate from the most recent common ancestor (MRCA) cell, in which a normal cell acquires all functional capacities to become a cancer cell. **b** | Genomic heterogeneity can result from the sequential, parallel accumulation of mutations, contributing to the heterogeneity and the evolution of ccRCC. In this example, ‘R’ represents the genomic characteristics of the primary tumour and ‘M’ represents the genomic characteristics of the metastatic sites, numbered accordingly. The major genetic lesions acquired after *VHL* mutation feature in different samples and are indicated on the branches. **c** | However, some evidence suggests that tumours can converge by way of parallel evolution. Here, a hypothetical braided river model depicts the sequential convergence of *SETD2* and *KDM5C* mutations through different spatiotemporally distinct genetic events. PreM, before M; PreP, before P. Part **a** inset is adapted with permission from REF. 207, Macmillan Publishers Limited.

Immune infiltration and tumour microenvironment

In addition to genetic alterations, gene expression, metabolic and immunological analyses of ccRCC have also yielded important mechanistic and clinical insights^{20,85–87}. Of these, perhaps the immune infiltration characteristics of ccRCC are of increasing interest, given the rise of immune checkpoint-blocking therapies in this disease (see below, Management). Notably, among 19 cancer types examined by The Cancer Genome Atlas research programme, ccRCC has the highest T cell infiltration score⁸⁷. Furthermore, higher nuclear grade and stage in ccRCC were correlated with an increase in T helper 2 cell and regulatory T cell infiltration^{87,88}.

Disease models

Although RCC cell lines have been used for mechanistic studies⁸⁹, ccRCC tumours in patients are highly vascular — a feature that cannot be recapitulated with *in vitro* cell studies. Furthermore, such cell lines can acquire additional genetic and/or epigenetic changes

during passages such that *in vitro* drug screens do not yield specific, translatable insights⁹⁰. Nevertheless, when these cell lines were injected subcutaneously into laboratory animals, xenografted tumours largely responded to anti-VEGF therapy⁹¹ and can be used to investigate resistance mechanisms^{92,93}.

More recently, patient-derived xenograft models have been established and have been shown to recapitulate the patient’s documented clinical response to targeted therapies, which could be used in preclinical drug trials⁹⁴. At the same time, efforts to develop mouse models that truly reflect human ccRCC genomics and morphology have been hampered by the fact that homozygous inactivation of *Vhl* in mice does not result in ccRCC⁶⁸. However, the identification of additional recurrent, prevalent mutations in human ccRCC has rekindled efforts to generate such models. For example, homozygous deletion of *Vhl* and *Pbrm1* in a mouse model resulted in multifocal, lipid-rich, glycogen-rich, transplantable ccRCC (J.J.H., unpublished observation).

Interestingly, homozygous deletion of *Vhl* and *Bap1* in a mouse model resulted in early lethality (<1 month), and some mice (within a cohort of seven) carrying homozygous deletion of *Vhl* and heterozygous deletion of *Bap1* developed tumour micronodules (0.25–1.8 mm in size) with unknown tumour incidence and molecular characteristics⁹⁵. Overall, animal models of RCC are currently limited but are eagerly being pursued.

Diagnosis, screening and prevention

Diagnosis

Historically, patients were diagnosed with RCC after presenting with flank pain, gross haematuria and a palpable abdominal mass. Nowadays, the majority of diagnoses result from incidental findings. This shift is a consequence of the widespread use of non-invasive radiological techniques, such as ultrasonography or abdominal CT imaging, performed for another reason. That being said, paraneoplastic syndromes — symptoms caused by hormones or cytokines excreted by tumour cells or by an immune response against the tumour — are not uncommon in RCC⁹⁶ and symptoms include hypercalcaemia, fever and erythrocytosis. Most of these symptoms are usually reversed after tumour resection¹¹. Diagnosis is usually strongly suspected by imaging

studies; although RCCs can show variable radiographic appearances⁹⁷. Typical radiological features for ccRCC include exophytic (outward) growth, heterogeneity due to intra-tumoral necrosis or haemorrhage and high uptake of contrast-enhancement agents⁹⁸.

Staging. The stage of RCC reflects the tumour size, the extent of invasion outside of the kidney, the involvement of lymph nodes and whether the tumour has metastasized (FIG. 5). CT imaging with contrast enhancement of the chest, abdominal cavity and pelvis is required for optimal staging. Such imaging enables the assessment of the primary tumour (such as the size and whether the tumour is organ-confined or extends to perinephric fat or the renal hilum), regional spread (lymph node involvement) and distant metastases (including lung, bone and distant lymph nodes). MRI can also provide additional information, especially to determine whether the tumour extends into the vasculature (a vena cava tumour thrombus). Bone scan, ¹⁸F-fluorodeoxyglucose PET and imaging of the brain are not systematically recommended for initial staging^{14,15}. Prognostic assessment will require further laboratory testing that includes, but is not limited to, haemoglobin levels, leukocyte and platelet counts, serum-corrected calcium levels and lactate dehydrogenase levels^{99,100}.




Figure 5 | Stages of kidney cancer and recommended treatments. Staging renal cell carcinoma (RCC) is based on size, position and lymph node involvement¹⁵. For example, a stage I or stage II tumour is enclosed wholly in the kidney. Stage III tumours can extend into major veins or adrenal glands within Gerota's fascia (the layer of connective tissue encapsulating the kidneys and adrenal glands) or can involve one regional lymph node. Stage IV tumours can invade beyond Gerota's fascia and/or have distant metastases. *Until the introduction of newer targeted therapies beginning in 2005, the 5-year survival of stage IV RCC was <10%.

Treatment is largely guided by stage^{15,24}. For example, those with stage I RCC who are fit for surgery are recommended partial nephrectomy. However, radical nephrectomy is also an option; for elderly patients or those who cannot undergo surgery owing to comorbidities, active surveillance or ablative therapies are recommended. In patients with stage III RCC, radical nephrectomy is recommended with lymph node dissection in those with clinically enlarged lymph nodes, but systemic therapies might be the only available option for those with extensive disease and poor performance status.

Table 3 | Nephrectomy scores to predict surgical complexity and outcomes

Nephrometry system	Parameters included	Outcomes prediction	External validation
R.E.N.A.L. nephrometry ²⁵	<ul style="list-style-type: none"> • Tumour size • Exophytic rate • Polar location • Renal sinus involvement • UCS involvement • Face location 	<ul style="list-style-type: none"> • Blood loss • Warm ischaemia time • UCS lesion • Overall complications • Functional outcomes • Benign or malignant tumour • Tumour grade 	Yes
PADUA classification ¹⁵³	<ul style="list-style-type: none"> • Tumour size • Exophytic rate • Polar location • Rim location • Renal sinus involvement • UCS involvement • Face location 	<ul style="list-style-type: none"> • Blood loss • Both warm and cold ischaemia time • UCS lesion • Overall complications • Functional outcomes 	Yes
Centrality Index ¹³⁵	<ul style="list-style-type: none"> • Tumour radius • Tumour depth (horizontal and vertical distances) 	<ul style="list-style-type: none"> • Both warm and cold ischaemia time • Functional outcomes 	Yes
Diameter-Axial-Polar system ¹³⁶	<ul style="list-style-type: none"> • Diameter • Axial distance • Polar distance 	<ul style="list-style-type: none"> • Blood loss • Warm ischaemia time • Functional outcomes 	No
Zonal NePhRO scoring system ¹³⁷	<ul style="list-style-type: none"> • Nearness to vital renal structures* • Physical zone • Tumour radius • Organization of the tumour 	Perioperative complications	No
Arterial Based Complexity scoring system ¹³⁸	Size of the renal arterial branches that need to be dissected or transected to achieve complete excision of the renal tumour	<ul style="list-style-type: none"> • Both warm and cold ischaemia time • Urinary fistula 	No

UCS, upper collecting system. *Cortex, medulla and collecting system or renal sinus.

Genomic implications. An age of onset of ≤ 46 years raises the possibility of a hereditary syndrome (TABLE 2) and, according to the American Society of Clinical Oncology, should trigger consideration for genetic counselling and might serve as a useful cut-off age when establishing genetic testing guidelines³⁷. Indeed, awareness of the non-renal malignancies and non-neoplastic features associated with RCC is of interest to the physician to identify hereditary syndromes⁴⁰. Furthermore, specific therapeutic options that are driven by the underlying biology are now being developed for these different RCC types related to cancer susceptibility syndromes¹⁰¹. Upon confirmation, patients and their families harbouring mutations are subject to specialized monitoring and treatment plans to minimize morbidity and prevent mortality.

Histopathological confirmation

Histopathological confirmation of malignancy is obtained either with renal core biopsy or on the partial or radical nephrectomy specimen. Initial biopsy is recommended before ablative therapy is undertaken (in those for whom surgery is not an option) or before initiating systemic therapy (in those who have metastatic disease)¹⁰². In 2016, the WHO classification of RCC was updated⁵ from previous (2004) WHO¹ and

International Society of Urological Pathology (ISUP) Consensus Conference⁴ (2013) systems. Although most RCCs can be easily classified on the basis of histological criteria, some tumours pose a diagnostic problem because they show a combination of features that are characteristic of different subtypes. For instance, the presence of clear cells is not unique to ccRCC but can be observed in pRCC, chRCC and MiT family translocation RCC⁶⁶. Similarly, papillary structures, which are a characteristic of pRCC, can be present in other RCC types¹⁰³. In challenging cases, careful evaluation of cytological features, growth pattern, immunophenotype and genetic alterations usually enables the proper diagnosis. However, a subset of RCCs (~4%) cannot be assigned to any specific category because they either present with combined morphologies or show unusual features and are, therefore, designated uRCC^{3,104,105}. Nevertheless, a recent molecular characterization of 62 aggressive uRCCs revealed distinct subsets, including *NF2* loss (26%), mTOR complex 1 (mTORC1) pathway activation (21%) and mutations in chromatin and DNA damage regulators (21%)¹⁰.

At macroscopic examination, the cut surface of the ccRCC tumours is golden yellow in colour with frequent haemorrhagic, necrotic and cystic areas. Microscopically, ccRCC usually consists of tumour cells with clear cytoplasm arranged in nests or tubules surrounded by a rich vascular network. The clear appearance of the cytoplasm is due to the accumulation of glycogen and lipids. A variable proportion of tumour cells with granular eosinophilic cytoplasm can be observed and, in some cases, these cells constitute the entire tumour mass^{3,104,105}. The most widely used grading system for ccRCC is the Fuhrman grading system, which defines four nuclear grades (1–4) in order of increasing nuclear size, irregularity and nucleolar prominence¹⁰⁶. The Fuhrman nuclear grade has been shown to have prognostic value in ccRCC^{30,107,108}.

It should be noted that all RCC types can contain foci of high-grade malignant spindle cells (that is, sarcomatoid differentiation). Thus, sarcomatoid RCC is no longer considered as an entity, but rather as a progression of any RCC type¹⁰⁹. Of note, recent genomic insights from sequencing-matched sarcomatoid and carcinomatous RCC demonstrated enrichment in *TP53* and *CDKN2A* mutations, which implicate these genetic defects as underlying causes of sarcomatoid differentiation in RCC^{110–112}.

Screening

Owing to the relatively low incidence of RCC, universal screening (such as that for asymptomatic microhaematuria) has not demonstrated a positive effect on outcomes in RCC¹¹³. Furthermore, other biomarkers have not yet been established for screening^{114,115}. Imaging remains the primary tool for the detection and screening of RCC. An ultrasonography screening study in 45,905 participants reported a 10-fold higher RCC incidence than expected for a general population with improved cancer-free survival when compared with symptomatic patients¹¹⁶.




Figure 6 | Indications for radical nephrectomy. a | Radical nephrectomy could be considered in cases with multiple small renal tumours (circled). **b** | Conversely, radical nephrectomy and contextual excision of neoplastic thrombus into renal vein or cava vein tumour thrombus is the gold-standard treatment for patients with venous involvement.

Although most cases are sporadic⁶², the majority of patients with RCC might have a genetic predisposition^{38,117}. Although, no guideline is available regarding the selection of patients for germline mutation testing, guidelines for monitoring those with confirmed hereditary syndromes that increase the risk of RCC are available³⁷.

Prevention: modifiable risk factors

Smoking, obesity and hypertension are associated with increased risks of developing RCC, whereas exercise and moderate consumption of alcohol and flavonoids reduce the risks of RCC.

Smoking. When compared to never smokers, a relative risk for ever smokers of 1.38 (95% CI: 1.27–1.50) was reported in a meta-analysis including 8,032 cases and 13,800 controls from five cohort studies¹¹⁸. A dose-dependent increase in risk in both men and women was found; individuals who had quit smoking >10 years prior had a lower risk than those who had quit <10 years prior. Another study has confirmed smoking as a risk factor for RCC¹¹⁹.

Obesity. A 5 kg/m² increase in BMI was found to be strongly associated with RCC¹²⁰. Similarly, a strong association between weight gain in early and mid-adulthood (18–35 years of age) and RCC was reported¹²¹. Moreover, central adiposity (relative risk: 1.8; 95% CI: 1.2–2.5) and the waist-to-hip ratio (range: 0.86–2.88) were positively associated with RCC in women¹²². The effect of BMI on overall survival was also studied in 1,975 patients treated with targeted agents. The authors reported a median overall survival of 25.6 months (95% CI: 23.2–28.6) in patients with a high BMI versus 17.1 months (95% CI: 15.5–18.5) in patients with a low BMI (adjusted hazard ratio: 0.84; 95% CI: 0.73–0.95)¹²³. Compared with stable weight, neither steady gain in weight nor weight loss was significantly associated with risk of RCC¹²¹.

Hypertension and medications. Higher BMI and hypertension were independently shown to increase the long-term risk of RCC in men, whereas a reduction in blood pressure lowered the risk¹²⁴. Aspirin use was found to be associated with an increased RCC risk in one out of five studies¹²⁵; by contrast, paracetamol (also known as acetaminophen) exposure showed no increased risk¹²⁶. The role of phenacetin (also known as acetophenetidin) exposure has been inconclusive¹²⁷. Statins were reported to significantly reduce the risk of RCC in a large analysis ($n = 483,733$), with a 48% risk reduction (adjusted odds ratio: 0.52; 95% CI: 0.45–0.60)¹²⁸. However, owing to the sporadic and low-frequency nature of RCC, the current guideline does not support the role of empirical treatment for the prevention of RCC in the general population; patients with hereditary syndromes should be monitored more closely and treated accordingly.

Management

For patients with surgically resectable RCC, the standard of care is surgical excision by either partial or radical nephrectomy with a curative intent. By contrast, those with inoperable or metastatic RCC typically undergo systemic treatment with targeted agents and/or immune checkpoint inhibitors. Deciding on which treatment to undertake has been largely guided by various nomograms³⁰. For example, the University of California, Los Angeles (UCLA) Integrated Staging System (UISS) and Stage, Size, Grade and Necrosis (SSIGN) score integrate clinical (1997 TNM stage) and pathological (Fuhrman nuclear grade) information to recommend the length and frequency of clinical follow-up and the selection of high-risk patients for adjuvant studies^{129–131}. Similarly, key prognostic factors have been identified, validated and adopted to guide and stratify patients with metastatic RCC for systemic treatment, including performance status, time from diagnosis to systemic treatment and haemoglobin, calcium and lactate dehydrogenase levels and neutrophil and platelet counts in the blood^{99,132,133}.

Surgery

Surgical treatment of RCC is related to the clinical stage of the disease and to the general condition of the patient (FIG. 5). Although typically reserved for localized disease, both partial and radical nephrectomy can also be used with cytoreductive intent in patients with metastatic disease. Indeed, randomized controlled trials (RCTs) demonstrating the benefit of this approach date from the 1990s, when cytokine-based therapies dominated the systemic therapy landscape. Furthermore, although most patients included in RCTs of targeted therapies also underwent cytoreductive nephrectomy, the current role of excision of the primary tumour in these patients has yet to be validated. However, according to the main international guidelines, many centres offer cytoreductive nephrectomy if there is a substantial disease volume at the primary site but only a low burden of metastatic disease¹³⁴.

Partial nephrectomy. The goal of partial nephrectomy is to completely remove the primary tumour while preserving the largest possible amount of healthy renal

parenchyma. Partial nephrectomy is indicated for patients with a T1 tumour (according to the Union for International Cancer Control TNM staging system) and a normal contralateral kidney (elective indication). Moreover, partial nephrectomy is strongly recommended (imperative absolute indications) in patients with RCC who have only one kidney (anatomically or functionally), in those with bilateral synchronous RCC and in those with von Hippel–Lindau syndrome. Similarly, imperative relative indications include conditions that can impair renal function (for example, kidney stones, hypertension, diabetes mellitus and pyelonephritis). Indeed, partial nephrectomy offers lower renal function impairment^{135–137} and equivalent oncological survival outcomes compared with radical nephrectomy in those with T1 tumours^{138,139}. More controversial is the favourable effect of partial nephrectomy on overall survival^{140,141} because conventional wisdom dictates that removal of the whole kidney is better in terms of oncological outcome. In this scenario, surgical feasibility remains the main factor that influences the final decision-making process.

In the past decade, nephrometry scoring systems have been proposed to predict the complexity of the partial nephrectomy procedure and to predict peri-operative outcomes according to the anatomical and

topographical tumour characteristics¹⁴² (TABLE 3). The R.E.N.A.L. and PADUA nephrometry systems are still the most popular and most used tools to preoperatively classify tumours¹⁴³. These first-generation systems, along with the Centrality Index system, mainly factor in tumour-related anatomical parameters, including face location (that is, anterior or posterior faces, according to their coverage by the anterior or posterior layers of the renal fascia, respectively), longitudinal polar location, rim location (that is, whether the tumour is located at the lateral or medial rim of the kidney), the degree of tumour extension into the parenchyma, renal sinus involvement, upper urinary collecting system involvement and the clinical maximal diameter of the tumour. Clinical studies demonstrated that such nephrometry systems were able to predict the risk of bleeding and postoperative complications in patients who underwent partial nephrectomy¹⁴². Thus, these systems represent valid tools for counselling patients and selecting the ideal candidate for partial nephrectomy according to surgeon experience¹⁴³. Second-generation nephrometry systems, such as Diameter-Axial-Polar system, Zonal NePhRO scoring system and Arterial Based Complexity system, should be externally validated and tested head-to-head against a first-generation system before being introduced into clinical practice.




Figure 7 | Therapeutic evolution and survival outcome of metastatic clear cell renal cell carcinoma through the four different eras. a | Before 2005, two drugs were available to treat renal cell carcinoma (RCC; with a median survival of ~15 months). This so-called dark age of treatments was followed by the modern age (2005–2014), which saw seven additional regimens gain approval (increasing the median survival to ~30 months). Currently, the golden age has already witnessed the introduction of three drugs, with more anticipated over the next decade. **b** | These advances promise to be translated to a significant number of patients (~50%), achieving durable remissions under active surveillance by 2025 with a median survival of ~5 years. The ultimate goal of the future diamond age of drug approvals is >80% of patients with metastatic clear cell RCC achieving long-term survival. Dashed lines represent predicted survival.

Laparoscopic partial nephrectomy (LPN) and robot-assisted partial nephrectomy (RAPN) are the main alternatives to classic open partial nephrectomy (OPN). However, RAPN and OPN are more appropriate in the treatment of more-complex cases (based on expert opinion). Conversely, LPN should be reserved for small tumours (usually ≤ 4 cm in size) in patients without complex features, as defined according to nephrometry systems (low-risk or intermediate-risk categories). Available meta-analyses have demonstrated that RAPN provides equivalent perioperative outcomes to LPN but a significantly shorter warm ischaemia time^{144,145}. Moreover, RAPN seems to be significantly better than OPN in terms of perioperative complications, estimated blood loss and hospital stay^{146,147}. Conversely, transfusion rate, ischaemia time, change in estimated glomerular filtration rate and early cancer outcomes are similar between the two approaches¹⁴⁷. International guidelines recommend the use of both approaches according to the surgeon and patient preferences.

Finally, partial nephrectomy can also involve simple enucleation — entirely sparing the healthy parenchyma around the tumour. Alternatively, classic enucleoresection, in which a thin layer of healthy parenchyma is removed, or polar or wedge resection, in which a wider excision of healthy parenchyma is performed, are also viable options. A minimal tumour-free surgical margin following partial nephrectomy seems appropriate to avoid the increased risk of local recurrence²⁴. Positive surgical margins have been reported in 1–6% of cases, regardless of the type of surgical technique used¹⁴⁸. Haematuria, perirenal haematoma and urinary fistulas

are the most common complications of partial nephrectomy procedures. Less-frequent postoperative complications can be represented by acute renal impairment and infection¹⁴⁹.

Radical nephrectomy. Classic radical nephrectomy consists of the removal of the kidney, perirenal fat tissue, adrenal gland and regional lymph nodes. However, in patients with a tumour ≤ 5 cm in size, located at the inferior pole, the adrenal gland can be spared. Similarly, regional lymph node dissection can be reserved for patients with clinically positive nodes detected by CT or during the surgical procedure¹⁵⁰. Radical nephrectomy can be considered in cases with multiple small renal tumours, in cases in which the tumour extends into the vasculature and can be a laparoscopic or open procedure (FIG. 6). In most patients with stage I and stage II tumours, radical nephrectomy is currently performed using a traditional laparoscopic approach; the open approach remains the gold standard for the treatment of more-complex cases. In experienced hands, the robot-assisted approach can represent a potential alternative to open surgery in cases with venous tumour thrombus.

Data recently extracted from the US National Cancer Database support the use of cytoreductive nephrectomy in those with metastatic disease even while they receive systemic targeted therapies. Indeed, the median overall survival was 17.1 months in cytoreductive nephrectomy cases versus 7.7 months in the non-cytoreductive nephrectomy group¹⁵¹.

Active surveillance and ablative therapies

Active surveillance and ablative techniques, such as cryotherapy or radiofrequency ablation, are alternative strategies for elderly patients and/or those with competing health risks and limited life expectancy that render them unsuitable for surgery^{15,24}.

A definite protocol for active surveillance has yet to be defined. The most common approach consists of alternating between ultrasonography imaging and CT or MRI every 3 months in the first year, every 6 months in the second year and annually thereafter. Intervention should be considered for growth to >3 – 4 cm or by >0.4 – 0.5 cm per year¹⁵². Data from the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry in the United States showed that, in a well-selected cohort of patients with up to 5 years of prospective follow-up, active surveillance was not inferior to primary intervention in terms of both overall survival and cancer-specific survival²⁶.

Ablative technology must be able to completely destroy all viable tumour tissue with no area of viable tumour left. Both cryotherapy and radiofrequency ablation can be performed using a laparoscopic or percutaneous approach under CT or ultrasound guidance. A meta-analysis of case series showed 89% and 90% of efficacy for cryoablation and radiofrequency ablation, respectively²⁵; complication rates were 20% and 19%, respectively. Available low-quality studies suggest a higher local recurrence rate for ablative therapies than for partial nephrectomy¹⁵³.

Box 1 | Limitations in the management of non-clear-cell renal cell carcinoma

From the perspective of surgical management, the presence of non-clear-cell histology rarely has a bearing on treatment and, in fact, histological subtype is often unknown preoperatively. Limited data are available to guide medical management of non-clear-cell renal cell carcinoma (nccRCC) as a consequence of the exclusion in general of non-clear-cell histologies from registration trials of targeted agents over the past 10 years. Importantly, the tumours classed as nccRCC are fundamentally different; there is no reason to suppose that a therapy that is effective for papillary RCC would be effective for chromophobe or indeed any other subtype of kidney cancer. Nevertheless, some trials have been carried out and have broadly established sunitinib as a reasonable first-line option in nccRCC, although the efficacy is less than for clear cell renal carcinoma (ccRCC). Most patients with metastatic nccRCC are treated with targeted agents that are approved for ccRCC, with the data favouring vascular endothelial growth factor inhibitors over mechanistic target of rapamycin complex 1 inhibitors^{22,204,205}. Unfortunately, most patients with nccRCC succumb to their disease within 18 months despite systemic treatment^{12,13,204–206}, and currently, there is no evidence base for the treatment of nccRCC with immune checkpoint inhibitors. Encouragingly, a recent phase II trial reported everolimus plus bevacizumab as an effective combination in treating nccRCC in patients whose tumours display papillary features, achieving an overall response rate of 43% and a median progression-free survival of 12.9 months¹⁹⁴. Arguably, everolimus plus bevacizumab should be considered as the comparison arm in trials in rare RCC subtypes that show predominant papillary morphology (papillary RCC type I and type II and unclassified RCC with papillary features). Overall, the advances made are encouraging, but drug therapies that are tailored specifically to subtype remain an unmet need. Initiatives such as rarekidneycancer.org set up by experts and patient advocates are important steps to encourage rapid communication among patients with rare kidney cancer, doctors who specialize in nccRCC and trialists.

Table 4 | Selected adverse events and quality of life of the approved agents

Drug	Adverse events	Improvement in quality of life?	Refs
Axitinib	Hypertension, diarrhoea, hypothyroidism and hand–foot syndrome	Yes versus sorafenib	157
Bevacizumab	Proteinuria, hypertension and bleeding	Not reported	160
Cabozantinib	Diarrhoea, hand–foot syndrome, hypertension, nausea and hypothyroidism	Not reported	159
Everolimus	Stomatitis, hypercholesterolaemia, hyperglycaemia and pneumonitis	No versus placebo	209
Nivolumab	Colitis, pneumonitis and endocrinopathies	Yes versus everolimus	165
Pazopanib	Diarrhoea, hypertension, liver function test abnormalities and hand–foot syndrome	• No versus placebo • Yes versus sunitinib	156
Sorafenib	Hypertension, diarrhoea, hand–foot syndrome and rash	Yes versus placebo	154
Sunitinib	Diarrhoea, hand–foot syndrome, mucositis and hypertension	Yes versus interferon- α	155
Temsirolimus	Stomatitis, hyperglycaemia, hypercholesterolaemia and oedema	Yes versus interferon- α	210

Medical management

The past 10 years have seen the approval of several targeted therapeutic agents and one immunotherapy agent for the treatment of metastatic RCC (FIG. 7). However, in the adjuvant setting after surgery, the situation is less clear and a randomized trial (ASSURE) of sunitinib versus sorafenib versus placebo showed no benefit for either drug therapy in terms of disease-free survival¹³¹. Notably, a recent study in the adjuvant setting reported a disease-free survival benefit for 1 year of sunitinib therapy in comparison with observation in the S-TRAC trial¹³⁰. Several other trials of adjuvant targeted therapies (such as PROTECT and SORCE) have completed accrual and will report outcomes in the next 12 months.

Targeted therapies. Given the highly vascular nature of RCCs, it is unsurprising that several therapies are available to exploit this feature. Indeed, tyrosine kinase inhibitors targeting the VEGF signalling axis that are approved in the first-line and second-line settings for the treatment of metastatic RCC in the United States and the European Union are sorafenib, sunitinib, pazopanib, axitinib, lenvatinib and cabozantinib^{154–159}. All approvals have been as single agents, except the combination of lenvatinib with everolimus; in addition, the anti-VEGF monoclonal antibody bevacizumab is approved for use with interferon- α ^{160,161}. Broadly speaking, sunitinib, pazopanib and the combination of bevacizumab and interferon- α are approved as first-line options, whereas axitinib and cabozantinib are approved as second-line options. The mTOR inhibitors everolimus and temsirolimus are approved as single agents in the second-line setting and in the first-line setting in patients with poor risk status^{162,163}. Indeed, arguably the landmark trial of first-line systemic therapy of metastatic RCC was the phase III study of sunitinib versus interferon- α reported in 2007, in which the superiority of sunitinib in terms

of response rate, progression-free survival and overall survival was reported¹⁵⁵. This trial established sunitinib as the standard of care and the drug remains the comparator for all currently recruiting phase III studies of new drugs.

No clinically usable markers are available to select patients for particular therapies, despite intensive efforts. As such, the average duration of disease control with these drugs is 8–9 months in the first-line setting and 5–6 months in the second-line setting. Most of the phase III RCTs leading to the approval of these agents have excluded patients with ccRCC (BOX 1) and, as such, this evidence base relates largely to ccRCC. Furthermore, all of these agents are given continuously until disease progression in the absence of major toxicity. In addition, alternative schedules, such as those electively interrupting therapy for prolonged periods, have not been reported from RCTs.

Immunotherapy. Cytokines such as interferon- α and high-dose IL-2 that enhance antitumour immune activity have been used since the 1990s to treat metastatic RCC and were standards of care before the introduction of sunitinib¹⁶⁴. Both drugs typically benefit only a small subset of patients (generally those with intrinsically favourable disease biology) and are associated with substantial toxicity, particularly in the case of high-dose IL-2. Many studies are currently investigating combinations of anti-VEGF therapy with a new generation of immunotherapy agents in the form of T cell immune checkpoint inhibitors, such as antibodies against programmed cell death protein 1 ligand 1 (PDL1), which include avelumab and atezolizumab, and antibodies against programmed cell death protein 1 (PD1), which include nivolumab and pembrolizumab. PD1 negatively regulates T cell function and its ligand PDL1 is highly expressed by cancer cells; accordingly, blockade of the PD1–PDL1 axis promotes T cell activation and immune killing of the cancer. Another combination under investigation (CheckMate 214; NCT02231749) is nivolumab with ipilimumab, an inhibitor of the T cell checkpoint cytotoxic T lymphocyte-associated protein 4 (CTLA4). CTLA4 also downregulates T cell function; its inhibition by these antibodies promotes T cell activation.

Nivolumab was approved in the United States and the European Union after the CheckMate 025 RCT showed an overall survival benefit compared with everolimus in patients who had failed prior therapy with sunitinib and pazopanib¹⁶⁵. However, the response rate to nivolumab was only 25% (5% for everolimus) and most patients treated did not experience significant tumour shrinkage. Although these checkpoint inhibitors show promise, predicting response is difficult. For example, in the CheckMate 025 trial, PDL1 expression did not correlate with response, as had been reported in other trials in other cancer types¹⁶⁵. The reason for this observation is unknown, but PDL1 expression is dynamic in space and time, and archival (paraffin-embedded) material from the primary tumour used in the CheckMate 025 trial might not have been representative of PDL1 expression at metastatic tumour sites.




Figure 8 | **Treatment algorithms for renal cell carcinoma.** Given the advances in renal cell carcinoma (RCC) research, how patients are treated — based on their individual tumour characteristics — will probably change in the future.

Finally, nivolumab is well tolerated compared with everolimus. Furthermore, it has been possible to combine nivolumab (and other anti-PD1 or anti-PDL1 therapies) with ‘clean’ (that is, more-specific, less-toxic and easier to combine) anti-VEGF therapies, such as axitinib and bevacizumab, leading to several phase III studies of such combinations in metastatic RCC.

Quality of life

Quality of life and patient-reported outcomes have become an important way to assess therapeutic strategies in the treatment of patients with RCC. Adverse events are important to consider and these are summarized in TABLE 4. Although oncological outcomes such as survival are more objective, validated measures of quality of life have been developed to help assess the patient experience.

For localized RCC, a systematic review was performed, which included data from 29 studies that included randomized and non-randomized studies¹⁴⁹. This review noted that quality-of-life outcomes after partial nephrectomy were superior to those of radical nephrectomy regardless of approach or technique. Interestingly, no good evidence suggested that cryotherapy or radiofrequency ablation had better quality-of-life outcomes than nephrectomy.

For metastatic RCC, measures of quality of life become more important as treatment is usually palliative and patients continually balance quality versus quantity of life. A validated 15-question tool called the Functional Assessment of Cancer Therapy-Kidney Cancer Symptom Index (FKSI) is the most specific to kidney cancer¹⁶⁶. A subscale of this, the FKSI-DRS (disease-related

symptoms) has nine kidney cancer-specific questions on the topics of lack of energy, pain, weight loss, bone pain, fatigue, shortness of breath, cough, fever and haematuria. Other more-general questionnaires exist and have been used in RCC clinical trials, including the Functional Assessment of Cancer Therapy General (FACT-G), the EuroQOL EQ-5D and Visual Analogue Scale (VAS)¹⁶⁷. These tools enable investigators to assess quality of life; however, limitations, including questionnaire burden, incomplete answering and defining a truly clinically significant minimal difference in quality-of-life scores, remain.

In the phase III registration trial of first-line sunitinib versus interferon- α in the metastatic setting, the FKSI, FKSI-DRS, FACT-G, EQ-5D and EQ-VAS demonstrated a consistent favourable difference in quality of life for sunitinib¹⁵⁵. This finding can probably be attributed to the favourable adverse-effect profile of sunitinib, which is associated with less fatigue than interferon- α , and higher efficacy of sunitinib (31% response rate) than interferon- α (6% response rate).

Quality of life was assessed with FKSI-19, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), the Cancer Therapy Satisfaction Questionnaire (CTSQ) and the Seville Quality of Life Questionnaire (SQLQ) in the COMPARZ clinical trial, which compared first-line sunitinib versus pazopanib¹⁵⁶. Measurements were taken at baseline and at day 28 of each treatment cycle, which is typically the point of highest sunitinib toxicity (including soreness in the mouth, throat, hands and feet). Improved quality-of-life scores were observed in those patients taking pazopanib versus those taking sunitinib.

The immune checkpoint inhibitors have also had quality-of-life analyses reported¹⁶⁷. The CheckMate 025 study of nivolumab used the FKSI-DRS score, which was performed at baseline and every 4 weeks up to study week 104, after which assessments were reduced. Median time to improvement in health-related quality of life was shorter in patients given nivolumab (4.7 months; 95% CI: 3.7–7.5) than in patients given everolimus (median not reached). The overall survival of patients was longer in those who had high baseline health-related quality-of-life scores who then improved than in those with similar baseline scores whose scores then deteriorated. The shortest overall survival was observed in patients with low baseline scores who then deteriorated.

Outlook

With the considerable advances in the molecular biology and management of RCC over the past several decades, it is not without reason that one could describe the current era of knowledge and available treatments as the ‘golden age’ of research. If we are to progress further, advances in diagnosis, local management and systemic therapy are needed to achieve >80% long-term survival that might define the future ‘diamond age’ of kidney cancer research and therapy (FIG. 7). Areas that currently show promise include developing strategies for treating high-risk patients, biomarkers to guide treatment and preventing and overcoming drug resistance.

Biomarkers to guide treatment

Although wide ranging clinical outcomes can be attributed to tumour heterogeneity in RCC, opportunities to further improve clinical outcomes on the basis of individual tumour characteristics (so-called precision medicine) are an emerging field. Given that nivolumab, cabozantinib and lenvatinib were only recently approved, and few correlative studies have been reported, potential biomarkers for VEGF and mTOR inhibitors currently have the most promise.

Biomarkers can range from clinical parameters (such as blood pressure) and endogenous substances (such as plasma proteins) to pathobiological features that are specific to individual tumours (such as mutations). For example, as an on-target clinical biomarker, hypertension (a systolic blood pressure of ≥ 140 mmHg) in patients receiving VEGF inhibitors has been shown to be associated with improved progression-free survival and overall survival¹⁶⁸. In addition, many studies have looked into circulating biomarkers¹⁶⁹, among which high levels of IL-6, IL-8, hepatocyte growth factor and osteopontin were associated with shorter progression-free survival in patients receiving pazopanib and sunitinib^{170,171}, whereas high levels of lactate dehydrogenase were associated with better overall survival in those receiving temsirolimus but not interferon- α ¹⁷².

Genetic biomarkers are also beginning to be studied for associations with treatment outcome in various metastatic settings^{173–175}. For example, RECORD-3, a large randomized phase II trial ($n = 471$), demonstrated the better first-line efficacy of sunitinib (a progression-free survival of 10.7 months) over first-line everolimus

(a progression-free survival of 7.9 months)²². Interestingly, genomic biomarker analysis of patients enrolled in RECORD-3 showed that *BAP1* mutations were associated with a progression-free survival of 8.1 months with first-line sunitinib but 5.5 months with first-line everolimus — a significant difference. By contrast, *PBRM1* mutations showed no such association²⁰, which is consistent with a VEGF inhibitor outlier study¹⁷³ and warrants further validation. That *BAP1* mutations were associated with inferior outcomes on everolimus²⁰ is surprising given their reported higher mTORC1 activity than *PBRM1*-mutant tumours⁷⁰. Furthermore, patients with *KDM5C* mutations were associated with a much longer first-line progression-free survival with sunitinib (20.6 months) than with everolimus (9.8 months)²⁰. As mutual exclusivity was detected between mutations in *BAP1* and *PBRM1* or *KDM5C*²⁰, molecular subgrouping of metastatic ccRCC based on these three genes could be of clinical value in the future. In addition, case-based mTOR inhibitor outlier studies recognized activation mutations of *MTOR* and biallelic inactivation of *TSC1* or *TSC2* as potential biomarkers for long-term responders^{69,73,75,76}.

Managing high-risk patients

A significant number (~30%) of patients with non-metastatic disease (based on clinical and pathological evaluation at the initial diagnosis) have occult metastases that will eventually become clinically evident. How to identify and better manage these high-risk patients presents a major challenge for operating urologists. As we begin to appreciate the effect that prevalent RCC mutations (in *PBRM1*, *SETD2*, *BAP1*, *KDM5C*, *PTEN* and *TP53*) have on clinical outcomes, incorporating specific mutational information into prognostic nomograms will become increasingly useful. For example, transcription signatures, such as ClearCode34 (REF. 86), and other biomarkers in the blood and urine might be incorporated into validated predictive biomarkers for RCC recurrence after surgery. Similarly, predicting treatment response to systemic therapy might be plausible and will reduce cost and improve care for patients with RCC. Our improving ability to identify high-risk patients with RCC and formulate personalized treatment and follow-up plans based on multi-omics holds the promise to quickly reduce the incidence of patients developing overt metastatic disease and render long-term survival.

Emerging therapies and changes to treatment

Several promising new drugs with novel mechanisms of action are in various stages of clinical trials. For immunotherapeutics, ipilimumab, an anti-CTLA4 antibody, in combination with nivolumab has shown a remarkable response rate of ~40% in the CheckMate 016 trial¹⁷⁶. In addition, the efficacy of autologous dendritic cell-based immunotherapy, which consists of expanding the patient's own dendritic cell numbers *in vitro* followed by the introduction of tumour RNA before re-infusion back into the patient, in combination with sunitinib has been examined and has shown early promise¹⁷⁷.

In the realm of targeted therapeutics, inhibitors specifically targeting HIF2 have been developed^{178,179}. As kidney cancer is characterized by aberrant glycolysis (with aberrant glutamine and tryptophan metabolism^{65,180,181}), it is of interest to learn whether the glutaminase inhibitor CB-839 (REF. 182) and the indoleamine-2,3-dioxygenase inhibitor INCB024360 (REF. 183) could yield additional clinical benefits when added to existing therapies. Finally, as many of these novel therapeutic agents act on modulating the anticancer response in patients, further understanding of the intricate relationship between an individual kidney cancer cell and its respective immune microenvironment would be crucial for the future success in designing combination treatments to improve survival^{187,184–187}.

Given the increasing understanding of tumour biology and the increasing number of treatment options, how treatments are selected in the future will undoubtedly change (FIG. 8). In addition to those already discussed, potential treatments of high value might include personalized vaccination¹⁸⁸, targeted radiotherapy to enhance antitumour immune response¹⁸⁹ and selective cytoreductive nephrectomy in patients who were initially inoperable but later showed marked shrinkage of tumours after systemic treatments. Furthermore, neoadjuvant or adjuvant¹⁹⁰ immunotherapy or targeted therapy could become integrated into the current treatment algorithms.

Preventing and overcoming drug resistance

Model systems and clinical experience have shown that inhibiting RCC activity with multiple drugs specific to different targets is superior to single-agent

approaches^{23,191,192}. However, such approaches tend to produce more toxicities — on-target and off-target. For example, the combination of sunitinib and everolimus in treating metastatic RCC subjected patients to severe toxicity¹⁹³. Nevertheless, bevacizumab, a more tolerable VEGF pathway inhibitor than sunitinib, plus everolimus is well tolerated and has been shown to be efficacious in treating ccRCC with papillary features¹⁹⁴. The success of polypharmacy relies on efficient and correct targeting of both primary and secondary (bypass) pathways^{69,195}. In ccRCC, VEGF is the primary pathway due to the universal *VHL* loss; secondary targets can include mTORC1, MET and IL-8, but not epidermal growth factor receptor or phosphoinositide 3-kinase pathways, when one takes into consideration the available clinical^{1158,159,169,196,197} and preclinical studies^{92,198–200}.

Given the availability of targeted therapies (FIG. 7), the immediate challenge is to design the most effective and specific regimen through combining or sequencing drugs to prevent resistance in individual patients²⁰¹. Interestingly, a recent study in patients with melanoma who relapsed after initial treatment response on PD1 blockade revealed invaluable insights on how tumour cells might develop resistance to immunotherapies, including defects in interferon signalling and in antigen presentation²⁰². As immune checkpoint inhibitors function independently of specific oncogenic pathways and incur distinct resistance mechanisms²⁰², the combination of these drugs with targeted therapies is of great clinical interest²⁰³ and theoretically can prevent the emergence of escape mechanisms from either agent.

- Eble, J. N., Sauter, G., Epstein, J. I. & Sesterhenn, I. A. (eds) *World Health Organization Classification Of Tumours* (IARC Press, 2004).
- Kovacs, G. *et al.* The Heidelberg classification of renal cell tumours. *J. Pathol.* **183**, 131–135 (1997).
This is the first consensus classification of RCC.
- Lopez-Beltran, A., Scarpelli, M., Montironi, R. & Kirkali, Z. 2004 WHO classification of the renal tumors of the adults. *Eur. Urol.* **49**, 798–805 (2006).
- Srigley, J. R. *et al.* The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am. J. Surg. Pathol.* **37**, 1469–1489 (2013).
- Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E. & Ulbright, T. M. The 2016 WHO classification of tumours of the urinary system and male genital organs — part A: renal, penile, and testicular tumours. *Eur. Urol.* **70**, 93–105 (2016).
This is the current consensus on RCC classification.
- Chen, F. J. *et al.* Multilevel genomics-based taxonomy of renal cell carcinoma. *Cell Rep.* **14**, 2476–2489 (2016).
This is a comprehensive genomic analysis of three major RCC subtypes (KIRC, KICH and KIRP), characterized by The Cancer Genome Atlas kidney cancer working groups.
- Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* **499**, 43–49 (2013).
This paper presents the most comprehensive genomic analysis of ccRCC and confirmed the loss of *VHL* and *3p* as truncal events.
- Cancer Genome Atlas Research Network *et al.* Comprehensive molecular characterization of papillary renal-cell carcinoma. *N. Engl. J. Med.* **374**, 135–145 (2016).
- Davis, C. F. *et al.* The somatic genomic landscape of chromophobe renal cell carcinoma. *Cancer Cell* **26**, 319–330 (2014).
- Chen, Y. B. *et al.* Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. *Nat. Commun.* **7**, 13131 (2016).
- Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. *Lancet* **373**, 1119–1132 (2009).
- Vera-Badillo, F. E. *et al.* Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. *Eur. Urol.* **67**, 740–749 (2015).
- Kroeger, N. *et al.* Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. *Cancer* **119**, 2999–3006 (2013).
- Escudier, B. *et al.* Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **27**, v58–v68 (2016).
- Motzer, R. J. *et al.* Kidney cancer, version 3.2015. *J. Natl Compr. Canc. Netw.* **13**, 151–159 (2015).
- Sankin, A., Hakimi, A. A., Hsieh, J. J. & Molina, A. M. Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. *Front. Oncol.* **5**, 67 (2015).
- Gerlinger, M. *et al.* Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N. Engl. J. Med.* **366**, 883–892 (2012).
This paper demonstrates the highly heterogeneous nature of somatic mutations in ccRCC through multiregion sequencing, which opened up the field of intra-tumour heterogeneity and convergent evolution through mutating the same gene within a given tumour.
- Gerlinger, M. *et al.* Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. *Nat. Genet.* **46**, 225–235 (2014).
- Sankin, A. *et al.* The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. *Cancer Med.* **3**, 1485–1492 (2014).
- Hsieh, J. J. *et al.* Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. *Eur. Urol.* **71**, 405–414 (2017).
This paper reports on the prevalent mutations in metastatic ccRCC tumours and the prognostic and predictive values of molecular classification of ccRCC based on genomic mutations in patients treated with targeted therapies in a randomized trial.
- Molina, A. M. *et al.* Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. *Eur. J. Cancer* **50**, 351–358 (2014).
- Motzer, R. J. *et al.* Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. *J. Clin. Oncol.* **32**, 2765–2772 (2014).
- Hsieh, J. J. *et al.* Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: a braided cancer river model of kidney cancer. *Semin. Cell Dev. Biol.* <http://dx.doi.org/10.1016/j.semcdb.2016.09.002> (2016).
- Ljungberg, B. *et al.* EAU guidelines on renal cell carcinoma: 2014 update. *Eur. Urol.* **67**, 913–924 (2015).
- El Dib, R., Touma, N. J. & Kapoor, A. Cryoablation versus radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. *BJU Int.* **110**, 510–516 (2012).
- Pierorazio, P. M. *et al.* Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. *Eur. Urol.* **68**, 408–415 (2015).
- Frank, I. *et al.* An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. *J. Urol.* **168**, 2395–2400 (2002).
This paper reports on the first commonly employed outcome prediction model (SSIGN) for patients with localized ccRCC.

28. Patard, J. J. *et al.* Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. *J. Clin. Oncol.* **22**, 3316–3322 (2004).
29. Wolff, I. *et al.* Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. *Eur. J. Surg. Oncol.* **42**, 744–750 (2016).
30. Meskawi, M. *et al.* A review of integrated staging systems for renal cell carcinoma. *Eur. Urol.* **62**, 303–314 (2012).
31. Motzer, R. J., Hutson, T. E., McCann, L., Deen, K. & Choueiri, T. K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. *N. Engl. J. Med.* **370**, 1769–1770 (2014).
32. Ferlay, J. *et al.* GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2013. *GLOBOCAN* <http://globocan.iarc.fr> (accessed on 4 Aug 2016).
33. Torre, L. A. *et al.* Global cancer statistics, 2012. *CA Cancer J. Clin.* **65**, 87–108 (2015).
34. Global Burden of Disease Cancer Collaboration *et al.* The Global Burden of Cancer 2013. *JAMA Oncol.* **1**, 505–527 (2015).
35. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. *CA Cancer J. Clin.* **66**, 7–30 (2016).
36. Ferlay, J. *et al.* Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur. J. Cancer* **49**, 1374–1403 (2013).
37. Shuch, B. *et al.* Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. *J. Clin. Oncol.* **32**, 431–437 (2014).
38. Nielsen, S. M. *et al.* Von Hippel–Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. *J. Clin. Oncol.* **34**, 2172–2181 (2016).
39. Haas, N. B. & Nathanson, K. L. Hereditary kidney cancer syndromes. *Adv. Chronic Kidney Dis.* **21**, 81–90 (2014).
40. Adeniran, A. J., Shuch, B. & Humphrey, P. A. Hereditary renal cell carcinoma syndromes: clinical, pathologic, and genetic features. *Am. J. Surg. Pathol.* **39**, e1–e18 (2015).
41. Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A. & Bray, F. International variations and trends in renal cell carcinoma incidence and mortality. *Eur. Urol.* **67**, 519–530 (2015).
42. Sun, M. *et al.* Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. *Eur. Urol.* **59**, 135–141 (2011).
43. Hakimi, A. A. *et al.* An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. *J. Natl Cancer Inst.* **105**, 1862–1870 (2013).
44. McLaughlin, J., Lipworth, L., Tarone, R. & Blot, W. in *Cancer Epidemiology and Prevention* (eds Schottenfeld, D. & Fraumeni, J. F.) 1087–1100 (Oxford Univ. Press, 2006).
45. Benichou, J., Chow, W. H., McLaughlin, J. K., Mandel, J. S. & Fraumeni, J. F. Jr. Population attributable risk of renal cell cancer in Minnesota. *Am. J. Epidemiol.* **148**, 424–430 (1998).
46. Chow, W. H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. *Nat. Rev. Urol.* **7**, 245–257 (2010).
47. Faramawi, M. F., Johnson, E., Fry, M. W., Sall, M. & Zhou, Y. Consumption of different types of meat and the risk of renal cancer: meta-analysis of case–control studies. *Cancer Causes Control* **18**, 125–133 (2007).
48. Lee, J. E. *et al.* Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. *J. Natl Cancer Inst.* **100**, 1695–1706 (2008).
49. Setiawan, V. W., Stram, D. O., Nomura, A. M., Kolonel, L. N. & Henderson, B. E. Risk factors for renal cell cancer: the multiethnic cohort. *Am. J. Epidemiol.* **166**, 932–940 (2007).
50. Tavani, A. *et al.* Lifetime physical activity and the risk of renal cell cancer. *Int. J. Cancer* **120**, 1977–1980 (2007).
51. Bergstrom, A. *et al.* Physical activity and risk of renal cell cancer. *Int. J. Cancer* **92**, 155–157 (2001).
52. Karami, S. *et al.* Family history of cancer and renal cell cancer risk in Caucasians and African Americans. *Br. J. Cancer* **102**, 1676–1680 (2010).
53. Kaelin, W. G. Von Hippel–Lindau disease. *Annu. Rev. Pathol.* **2**, 145–173 (2007).
54. Gnarr, J. R. *et al.* Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nat. Genet.* **7**, 85–90 (1994).
55. Purdue, M. P. *et al.* Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. *Nat. Genet.* **43**, 60–65 (2011).
56. Wu, X. *et al.* A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. *Hum. Mol. Genet.* **21**, 456–462 (2012).
57. Henrion, M. *et al.* Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. *Hum. Mol. Genet.* **22**, 825–831 (2013).
58. Gudmundsson, J. *et al.* A common variant at 8q24.21 is associated with renal cell cancer. *Nat. Commun.* **4**, 2776 (2013).
59. Schodel, J. *et al.* Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. *Nat. Genet.* **44**, 420–425 (2012).
60. Bigot, P. *et al.* Functional characterization of the 12p12.1 renal cancer-susceptibility locus implicates BHLHE41. *Nat. Commun.* **7**, 12098 (2016).
61. Hakimi, A. A., Pham, C. G. & Hsieh, J. J. A clear picture of renal cell carcinoma. *Nat. Genet.* **45**, 849–850 (2013).
62. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. *Nat. Rev. Urol.* **7**, 277–285 (2010). **This paper proposes RCC as a metabolic disease with mutations concentrating on metabolic pathways.**
63. Masson, N. & Ratcliffe, P. J. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. *Cancer Metab.* **2**, 3 (2014).
64. Semenza, G. L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. *J. Clin. Invest.* **123**, 3664–3671 (2013). **This paper presents an updated, comprehensive view of HIF1 function in tumour biology.**
65. Hakimi, A. A. *et al.* An integrated metabolic atlas of clear cell renal cell carcinoma. *Cancer Cell* **29**, 104–116 (2016). **This paper reports the largest global metabolomics study of ccRCC and demonstrates its prognostic values.**
66. Reuter, V. E. & Tickoo, S. K. Differential diagnosis of renal tumours with clear cell histology. *Pathology* **42**, 374–383 (2010).
67. Lee, C. H. *et al.* Bevacizumab monotherapy as salvage therapy for advanced clear cell renal cell carcinoma pretreated with targeted drugs. *Clin. Genitourin. Cancer* **14**, 56–62 (2016).
68. Kapitsinou, P. P. & Haase, V. H. The VHL tumor suppressor and HIF: insights from genetic studies in mice. *Cell Death Differ.* **15**, 650–659 (2008).
69. Wei, E. Y. & Hsieh, J. J. A river model to map convergent cancer evolution and guide therapy in RCC. *Nat. Rev. Urol.* **12**, 706–712 (2015). **This paper proposes a novel cancer evolution model of ccRCC through gene–pathway–phenotype convergence.**
70. Pena-Llopis, S. *et al.* BAP1 loss defines a new class of renal cell carcinoma. *Nat. Genet.* **44**, 751–759 (2012).
71. Hakimi, A. A. *et al.* Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. *Eur. Urol.* **63**, 848–854 (2013).
72. Sato, Y. *et al.* Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat. Genet.* **45**, 860–867 (2013).
73. Xu, J. *et al.* Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. *J. Clin. Invest.* **126**, 3526–3540 (2016).
74. Grabiner, B. C. *et al.* A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. *Cancer Discov.* **4**, 554–563 (2014). **Together with reference 73, these two papers demonstrate that activating mutations in MTOR are common genetic events in ccRCC.**
75. Voss, M. H. *et al.* Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. *Clin. Cancer Res.* **20**, 1955–1964 (2014). **This paper demonstrates the association between mutations in the core mTORC1-regulatory pathway and long-term therapeutic benefit from rapalogues.**
76. Kwiatkowski, D. J. *et al.* Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. *Clin. Cancer Res.* **22**, 2445–2452 (2016).
77. Hakimi, A. A. *et al.* Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA Research Network. *Clin. Cancer Res.* **19**, 3259–3267 (2013).
78. Kapur, P. *et al.* Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. *Lancet Oncol.* **14**, 159–167 (2013). **Together with reference 77, these two papers demonstrate the prognostic values of PBRM1, BAP1 and SETD2 mutations in ccRCC.**
79. Nam, S. J., Lee, C., Park, J. H. & Moon, K. C. Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma. *Urol. Oncol.* **33**, 340.e9–340.e16 (2015).
80. Manley, B. J. *et al.* Integration of recurrent somatic mutations with clinical outcomes: a pooled analysis of 1049 patients with clear cell renal cell carcinoma. *Eur. Urol. Focus* <http://dx.doi.org/10.1016/j.euf.2016.06.015> (2016).
81. Nowell, P. C. The clonal evolution of tumor cell populations. *Science* **194**, 23–28 (1976).
82. Venkatesan, S. & Swanton, C. Tumor evolutionary principles: how intratumour heterogeneity influences cancer treatment and outcome. *Am. Soc. Clin. Oncol.* **35**, e141–e149 (2016).
83. Kanu, N. *et al.* SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. *Oncogene* **34**, 5699–5708 (2015).
84. Gulati, S. *et al.* Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. *Eur. Urol.* **66**, 936–948 (2014).
85. Beuselinck, B. *et al.* Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. *Clin. Cancer Res.* **21**, 1329–1339 (2015).
86. Brooks, S. A. *et al.* ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. *Eur. Urol.* **66**, 77–84 (2014).
87. Senbabaoglu, Y. *et al.* Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. *Genome Biol.* **17**, 231 (2016).
88. Geissler, K. *et al.* Immune signature of tumor infiltrating immune cells in renal cancer. *Oncoimmunology* **4**, e985082 (2015).
89. Sinha, R. *et al.* Evaluating renal cell carcinoma cell lines as tumor models. *Nat. Commun.* (in press). **This paper presents the most comprehensive in silico analysis of publically available RCC cell lines.**
90. Winter, S. *et al.* Methyloles of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. *Sci. Rep.* **6**, 29930 (2016).
91. Huang, D. *et al.* Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. *Cancer Res.* **70**, 1053–1062 (2010). **This paper provides clear evidence that sunitinib acts primarily on the tumour endothelium using cancer cell lines.**
92. Huang, D. *et al.* Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. *Cancer Res.* **70**, 1063–1071 (2010).
93. Zhou, L. *et al.* Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. *Oncogene* **35**, 2687–2697 (2016).
94. Dong, Y. *et al.* Development of a clear cell renal cell carcinoma xenograft model: a case for the use of biopsy tissue over surgical tissue. *J. Urol.* **195**, e916 (2016). **Using patient-derived xenograft ccRCC models and tumour cells from patients with known primary response or resistance to sunitinib, this paper confirms that the principal therapeutic effect derived from sunitinib is through targeting tumour blood vessels.**
95. Wang, S. S. *et al.* Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. *Proc. Natl Acad. Sci. USA* **111**, 16538–16543 (2014).
96. Palapattu, G. S., Kristo, B. & Rajfer, J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. *Eur. Urol.* **4**, 163–170 (2002).

97. Low, G., Huang, G., Fu, W., Moloo, Z. & Girgis, S. Review of renal cell carcinoma and its common subtypes in radiology. *World J. Radiol.* **8**, 484–500 (2016).
98. Karlo, C. A. *et al.* Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. *Radiology* **270**, 464–471 (2014). **This is the first radiogenomics study of ccRCC.**
99. Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon- α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. *J. Clin. Oncol.* **20**, 289–296 (2002). **This paper presents the value of Memorial Sloan Kettering Cancer Center risk factors in stratifying patients with metastatic kidney cancer.**
100. Heng, D. Y. *et al.* External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. *Lancet Oncol.* **14**, 141–148 (2013).
101. Linehan, W. M., Srinivasan, R. & Garcia, J. A. Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. *Semin. Oncol.* **40**, 511–520 (2013).
102. Marconi, L. *et al.* Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. *Eur. Urol.* **69**, 660–673 (2016).
103. Tickoo, S. K. & Reuter, V. E. Differential diagnosis of renal tumors with papillary architecture. *Adv. Anat. Pathol.* **18**, 120–132 (2011).
104. Moch, H. An overview of renal cell cancer: pathology and genetics. *Semin. Cancer Biol.* **23**, 3–9 (2013).
105. Algaba, F. *et al.* Current pathology keys of renal cell carcinoma. *Eur. Urol.* **60**, 634–643 (2011).
106. Fuhrman, S. A., Lasky, L. C. & Limas, C. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am. J. Surg. Pathol.* **6**, 655–663 (1982). **This paper reports and establishes the nuclear grading of RCC.**
107. Chevillet, J. C., Blute, M. L., Zincke, H., Lohse, C. M. & Weaver, A. L. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. *J. Urol.* **166**, 453–456 (2001).
108. Grignon, D. J. & Che, M. Clear cell renal cell carcinoma. *Clin. Lab. Med.* **25**, 305–316 (2005).
109. de Peralta-Venturina, M. *et al.* Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. *Am. J. Surg. Pathol.* **25**, 275–284 (2001).
110. Bi, M. *et al.* Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. *Proc. Natl. Acad. Sci. USA* **113**, 2170–2175 (2016).
111. Malouf, G. G. *et al.* Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. *Eur. Urol.* **70**, 348–357 (2016).
112. Manley, B. J. & Hsieh, J. J. Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components. *Transl. Cancer Res.* **5**, S160–S165 (2016).
113. Thompson, I. M. The evaluation of microscopic hematuria: a population-based study. *J. Urol.* **138**, 1189–1190 (1987).
114. Zhang, L. *et al.* iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell renal cell carcinoma. *Biosci. Trends* **10**, 210–219 (2016).
115. Morrissey, J. J. *et al.* Evaluation of urine aquaporin-1 and perilipin-2 concentrations as biomarkers to screen for renal cell carcinoma: a prospective cohort study. *JAMA Oncol.* **1**, 204–212 (2015).
116. Tosaka, A. *et al.* Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. *J. Urol.* **144**, 1097–1099 (1990).
117. Gudbjartsson, T. *et al.* A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. *Int. J. Cancer* **100**, 476–479 (2002).
118. Hunt, J. D., van der Hel, O. L., McMillan, G. P., Boffetta, P. & Brennan, P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. *Int. J. Cancer* **114**, 101–108 (2005).
119. Theis, R. P., Dolwick, Grieb, S. M., Burr, D., Siddiqui, T. & Asal, N. R. Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case-control study. *BMC Cancer* **8**, 387 (2008).
120. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F. & Zwahlen, M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* **371**, 569–578 (2008).
121. Adams, K. F. *et al.* Body size and renal cell cancer incidence in a large US cohort study. *Am. J. Epidemiol.* **168**, 268–277 (2008).
122. Luo, J. *et al.* Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States). *Am. J. Epidemiol.* **166**, 752–759 (2007).
123. Albiges, L. *et al.* Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. *J. Clin. Oncol.* **34**, 3655–3663 (2016).
124. Chow, W. H., Gridley, G., Fraumeni, J. F. Jr & Jarvholm, B. Obesity, hypertension, and the risk of kidney cancer in men. *N. Engl. J. Med.* **343**, 1305–1311 (2000).
125. Gago-Dominguez, M., Yuan, J. M., Castela, J. E., Ross, R. K. & Yu, M. C. Regular use of analgesics is a risk factor for renal cell carcinoma. *Br. J. Cancer* **81**, 542–548 (1999).
126. McCreddie, M., Stewart, J. H. & Day, N. E. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. *Int. J. Cancer* **53**, 245–249 (1993).
127. Dhote, R., Thiounn, N., Debre, B. & Vidal-Trecan, G. Risk factors for adult renal cell carcinoma. *Urol. Clin. North Am.* **31**, 237–247 (2004).
128. Khurana, V., Caldito, G. & Ankem, M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. *Urology* **71**, 118–122 (2008).
129. Stewart-Merrill, S. B. *et al.* Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. *J. Clin. Oncol.* **33**, 4151–4157 (2015).
130. Ravaud, A. *et al.* Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. *N. Engl. J. Med.* **375**, 2246–2254 (2016).
131. Haas, N. B. *et al.* Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet* **387**, 2008–2016 (2016).
132. Negrier, S. *et al.* Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunotherapie. *Ann. Oncol.* **13**, 1460–1468 (2002).
133. Heng, D. Y. *et al.* Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J. Clin. Oncol.* **27**, 5794–5799 (2009).
134. Bex, A., Ljungberg, B., van Poppel, H., Powles, T. & European Association of Urology. The role of cytoreductive nephrectomy: European Association of Urology recommendations in 2016. *Eur. Urol.* **70**, 901–905 (2016).
135. Huang, W. C. *et al.* Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. *Lancet Oncol.* **7**, 735–740 (2006). **This paper reports on the increased incidence of chronic kidney disease, leading to the ensuing trials comparing radical and partial nephrectomy in RCC.**
136. Scosyrev, E., Messing, E. M., Sylvester, R., Campbell, S. & Van Poppel, H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. *Eur. Urol.* **65**, 372–377 (2014).
137. Pignot, G. *et al.* Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff. *Urol. Oncol.* **32**, 1024–1030 (2014).
138. Van Poppel, H. *et al.* A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Urol. Oncol.* **59**, 543–552 (2011). **This is the first randomized phase III trial comparing the oncological outcome between partial and radical nephrectomy.**
139. MacLennan, S. *et al.* Systematic review of oncological outcomes following surgical management of localised renal cancer. *Eur. Urol.* **61**, 972–993 (2012).
140. Weight, C. J. *et al.* Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. *Eur. Urol.* **58**, 293–298 (2010).
141. Sun, M. *et al.* A non-cancer-related survival benefit is associated with partial nephrectomy. *Eur. Urol.* **61**, 725–731 (2012).
142. Klatte, T. *et al.* A literature review of renal surgical anatomy and surgical strategies for partial nephrectomy. *Eur. Urol.* **68**, 980–992 (2015).
143. Crestani, A. *et al.* Introduction to small renal tumours and prognostic indicators. *Int. J. Surg.* **36**, 495–503 (2016).
144. Aboumarzouk, O. M. *et al.* Robotic versus laparoscopic partial nephrectomy: a systematic review and meta-analysis. *Eur. Urol.* **62**, 1023–1033 (2012).
145. Zhang, X. *et al.* Comparison of peri-operative outcomes of robot-assisted versus laparoscopic partial nephrectomy: a meta-analysis. *BJU Int.* **112**, 1133–1142 (2013).
146. Ficarra, V. *et al.* A multicentre matched-pair analysis comparing robot-assisted versus open partial nephrectomy. *BJU Int.* **113**, 936–941 (2014).
147. Wu, Z. *et al.* Robotic versus open partial nephrectomy: a systematic review and meta-analysis. *PLoS ONE* **9**, e94878 (2014).
148. Marszałek, M. *et al.* Positive surgical margins after nephron-sparing surgery. *Eur. Urol.* **61**, 757–763 (2012).
149. MacLennan, S. *et al.* Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. *Eur. Urol.* **62**, 1097–1117 (2012).
150. Blom, J. H. *et al.* Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. *Eur. Urol.* **55**, 28–34 (2009).
151. Hanna, N. A. *et al.* Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Data Base study. *J. Clin. Oncol.* **34**, 3267–3275 (2016).
152. Lane, B. R., Tobert, C. M. & Riedinger, C. B. Growth kinetics and active surveillance for small renal masses. *Curr. Opin. Urol.* **22**, 353–359 (2012).
153. Campbell, S. C. *et al.* Guideline for management of the clinical T1 renal mass. *J. Urol.* **182**, 1271–1279 (2009).
154. Escudier, B. *et al.* Sorafenib in advanced clear-cell renal-cell carcinoma. *N. Engl. J. Med.* **356**, 125–134 (2007). **This pivotal trial led to the approval of the first anti-VEGFR targeted therapy sorafenib for metastatic ccRCC.**
155. Motzer, R. J. *et al.* Sunitinib versus interferon α in metastatic renal-cell carcinoma. *N. Engl. J. Med.* **356**, 115–124 (2007). **This pivotal trial establishes sunitinib as the first-line treatment for ccRCC, which greatly improved the survival outcome.**
156. Motzer, R. J., McCann, L. & Deen, K. Pazopanib versus sunitinib in renal cancer. *N. Engl. J. Med.* **369**, 1970 (2013).
157. Rini, B. I. *et al.* Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet* **378**, 1931–1939 (2011).
158. Motzer, R. J. *et al.* Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol.* **16**, 1473–1482 (2015).
159. Choueiri, T. K. *et al.* Cabozantinib versus everolimus in advanced renal-cell carcinoma. *N. Engl. J. Med.* **373**, 1814–1823 (2015).
160. Escudier, B. *et al.* Bevacizumab plus interferon α -2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet* **370**, 2103–2111 (2007).
161. Rini, B. I. *et al.* Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. *J. Clin. Oncol.* **26**, 5422–5428 (2008).
162. Motzer, R. J. *et al.* Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet* **372**, 449–456 (2008).
163. Hudes, G. *et al.* Temsirolimus, interferon α , or both for advanced renal-cell carcinoma. *N. Engl. J. Med.* **356**, 2271–2281 (2007).
164. McDermott, D. F. *et al.* Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. *J. Clin. Oncol.* **23**, 133–141 (2005). **This paper reports on a randomized phase III trial, which demonstrated a 23% response rate for high-dose IL-2.**

165. Motzer, R. J. *et al.* Nivolumab versus everolimus in advanced renal-cell carcinoma. *N. Engl. J. Med.* **373**, 1803–1813 (2015).
This pivotal trial led the approval of the immune checkpoint inhibitor nivolumab, which is an anti-PD1 antibody, for the treatment of metastatic RCC.
166. Cella, D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. *Cancer Treat. Rev.* **35**, 733–737 (2009).
167. Cella, D. *et al.* Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. *Lancet Oncol.* **17**, 994–1003 (2016).
168. Donskov, F. *et al.* Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. *Br. J. Cancer* **113**, 1571–1580 (2015).
169. Funakoshi, T., Lee, C. H. & Hsieh, J. J. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. *Cancer Treat. Rev.* **40**, 533–547 (2014).
170. Tran, H. T. *et al.* Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. *Lancet Oncol.* **13**, 827–837 (2012).
171. Voss, M. H. *et al.* Circulating biomarkers and outcome from a randomised phase II trial of sunitinib versus everolimus for patients with metastatic renal cell carcinoma. *Br. J. Cancer* **114**, 642–649 (2016).
172. Armstrong, A. J., George, D. J. & Halabi, S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. *J. Clin. Oncol.* **30**, 3402–3407 (2012).
173. Fay, A. P. *et al.* Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma. *J. Natl Compr. Canc. Netw.* **14**, 820–824 (2016).
174. Ho, T. H. *et al.* Correlation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy response. *Eur. Urol. Focus* **2**, 204–209 (2016).
175. Hsieh, J. *et al.* Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): results from RECORD-3. *J. Clin. Oncol.* **33**, abstr. 4509 (2015).
176. Hammers, H. J. *et al.* Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). *J. Clin. Oncol.* **33**, abstr. 4516 (2015).
177. Amin, A. *et al.* Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. *J. Immunother. Cancer* **3**, 14 (2015).
178. Chen, W. *et al.* Targeting renal cell carcinoma with a HIF-2 antagonist. *Nature* **539**, 112–117 (2016).
179. Cho, H. *et al.* On-target efficacy of a HIF2alpha antagonist in preclinical kidney cancer models. *Nature* **539**, 107–111 (2016).
180. Wettersten, H. I. *et al.* Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. *Cancer Res.* **75**, 2541–2552 (2015).
181. Rodrigues, D. *et al.* Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. *Transl Res.* **180**, 1–11 (2017).
182. Harding, J. J. *et al.* Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. ASCO <http://meetinglibrary.asco.org/content/109133?media=sl> (2015).
183. Beatty, G. L. *et al.* Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. ASCO <http://meetinglibrary.asco.org/content/83930?media=vm> (2013).
184. Tartour, E. *et al.* Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. *Cancer Metastasis Rev.* **30**, 83–95 (2011).
185. Remark, R. *et al.* Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. *Clin. Cancer Res.* **19**, 4079–4091 (2013).
186. Giraldo, N. A. *et al.* Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. *Clin. Cancer Res.* **21**, 3031–3040 (2015).
187. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. *Nat. Rev. Cancer* **12**, 298–306 (2012).
188. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. *Science* **348**, 69–74 (2015).
189. Demaria, S. *et al.* Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. *Int. J. Radiat. Oncol. Biol. Phys.* **58**, 862–870 (2004).
190. Janowitz, T., Welsh, S. J., Zaki, K., Mulders, P. & Eisen, T. Adjuvant therapy in renal cell carcinoma—past, present, and future. *Semin. Oncol.* **40**, 482–491 (2013).
191. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **144**, 646–674 (2011).
192. Bozic, I. *et al.* Evolutionary dynamics of cancer in response to targeted combination therapy. *eLife* **2**, e00747 (2013).
193. Molina, A. M. *et al.* Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. *Cancer* **118**, 1868–1876 (2012).
194. Voss, M. H. *et al.* Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. *J. Clin. Oncol.* **4**, 3846–3853 (2016).
195. Hsieh, J. J. & Cheng, E. H. A braided cancer river connects tumor heterogeneity and precision medicine. *Clin. Transl Med.* **5**, 42 (2016).
196. Powles, T. *et al.* Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. *J. Clin. Oncol.* **34**, 1660–1668 (2016).
197. Carlo, M. I. *et al.* A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma. *Oncologist* **21**, 787–788 (2016).
198. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. *Nat. Rev. Cancer* **8**, 592–603 (2008).
199. Nakaigawa, N. *et al.* Inactivation of von Hippel–Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. *Cancer Res.* **66**, 3699–3705 (2006).
200. Mizukami, Y. *et al.* Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. *Nat. Med.* **11**, 992–997 (2005).
201. Albiges, L. *et al.* A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. *Eur. Urol.* **67**, 100–110 (2015).
202. Zaretsky, J. M. *et al.* Mutations associated with acquired resistance to PD-1 blockade in melanoma. *N. Engl. J. Med.* **375**, 819–829 (2016).
203. Massari, F. *et al.* PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. *Cancer Treat. Rev.* **41**, 114–121 (2015).
204. Armstrong, A. J. *et al.* Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. *Lancet Oncol.* **17**, 378–388 (2016).
205. Tannir, N. M. *et al.* Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. *Eur. Urol.* **69**, 866–874 (2016).
206. Dutcher, J. P. *et al.* Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. *Med. Oncol.* **26**, 202–209 (2009).
207. Yates, L. R. & Campbell, P. J. Evolution of the cancer genome. *Nat. Rev. Genet.* **13**, 795–806 (2012).
208. Shuch, B. *et al.* Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. *Eur. Urol.* **67**, 85–97 (2015).
209. Beaumont, J. L. *et al.* Patient-reported outcomes in a phase III study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. *Oncologist* **16**, 632–640 (2011).
210. Yang, S., de Souza, P., Alemao, E. & Purvis, J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. *Br. J. Cancer* **102**, 1456–1460 (2010).

Acknowledgements

J.J.H. is supported by the J. Randall & Kathleen L. MacDonald Family Research Fund, the Tom and Mila Tuttle Family Research Fund, the Jill and Rafic Dahan Family Research Fund, and the Jill and Jeffrey Weiss Family Research Fund for the cure of metastatic kidney cancer. J.L. is supported by the National Institute of Health Research (NIHR) Royal Marsden/Institute of Cancer Research Biomedical Research Centre for Cancer. M.P.P. is supported by the Intramural Research Program of the National Cancer Institute, US National Institutes of Health.

Author contributions

Introduction (J.J.H.); Epidemiology (M.P.P.); Mechanisms/pathophysiology (S.S., J.J.H. and C.S.); Diagnosis screening and prevention (L.A. and M.S.); Management (V.F. and J.L.); Quality of life (D.Y.H.); Outlook (J.J.H.); Overview of Primer (J.J.H.).

Competing interests

J.J.H. is a consultant for Novartis, Eisai and Chugai and has received research funding from Pfizer, Novartis, Eisai and Cancer Genomics Inc. C.S. is a consultant for Roche, Pfizer, Boehringer Ingelheim, Novartis, Celgene, Servier, Eli Lilly and GlaxoSmithKline, and owns stock options from Achilles Therapeutics, Epic Biosciences, Grail and ApoGen Biotech. L.A. is a consultant for Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer and Cerulean, and has received research funding from Pfizer and Novartis. M.S. is a consultant for Pfizer, Bristol-Myers Squibb, Ipsen, Exelixis, Eisai, Roche, Novartis and Astellas. D.Y.H. is a consultant for Pfizer, Novartis and Bristol-Myers Squibb. J.L. has received research funding from Novartis, Pfizer, Bristol-Myers Squibb and Merck Sharp & Dohme. M.P.P., S.S. and V.F. declare no competing interests.

How to cite this article

Hsieh, J. J. *et al.* Renal cell carcinoma. *Nat. Rev. Dis. Primers* **3**, 17009 (2017).